U.S. and European Regulatory Strategies for Asian MedTech Startups

On-demand webinar

Multimedia
Published on:
April 13, 2022

This webinar is part of the free webinar series “Expanding Beyond APAC” launched to discuss the strategies, challenges, and best practices of entering new markets and scaling beyond the Asia Pacific for MedTech companies.  

The webinar series is prepared together with APACMed, Asia Pacific’s regional trade association which represents manufacturers and providers of medical equipment and devices, in-vitro diagnostics, digital health; as well as local associations and other key stakeholders within the medical technology industry. 

The webinar “U.S. and European Regulatory Strategies for Asian MedTech Startups” focused on the U.S. FDA and EU MDR/IVDR regulatory pathways and strategies for medical device startups based in the Asia Pacific. We examined the role of US FDA pre-sub meetings and the pros and cons of 510(k), PMA, De Novo pathways as well as the implications of obtaining EUA and breakthrough designation. We discussed the challenges of the new EU MDR and IVDR regulations and provided tips on how to work with European Notified Bodies.

WHO SHOULD WATCH THIS WEBINAR:

MedTech, digital health and IVD startups, and Small & Medium-sized Enterprises based in the Asia Pacific planning to expand commercially to Europe and North America. 

WHAT YOU WILL LEARN:
  • What are the alternative regulatory pathways and strategies in the U.S.
  • What are the hot topics and how to streamline the submission process in the U.S.
  • What are the EU MDR/IVDR requirements and impact on startups

Meet the speaker

Mary McNamara-Cullinane – Senior Vice President, Regulatory Affairs, Alira Health

Mary McNamara-Cullinane

Mary is an accomplished and experienced regulatory professional, drawing on 25 years of experience in the healthcare and life sciences field. Mary’s clearances include: 510k (abbreviated and special), PMA approvals, IDE approvals, De Novo, 510k submissions for novel medical devices, and 513g requests for classifications. Mary is also a frequent conference speaker and panelist on a range of topics including MedTech, regulatory affairs, and women in healthcare.

Related news

Publications November 22, 2022
External Control Arms: The Way to Go?
The growing implementation of Single Arm Trials (SATs) with External Control Arms (ECAs) has been the subject of heated debate across Europe.
Clinical Trials Regulatory
Multimedia October 27, 2022
RARECast: Leveraging Technology to Empower Patients and Decentralize Clinical Trials
Technology plays a central role in the future of patient empowerment and decentralized clinical trials. Listen to the podcast to learn more.
Decentralized Clinical Trials MedTech
Multimedia October 13, 2022
Exclusive MedTech Webinar Series “Expanding Beyond APAC”
Join this series of webinars to learn about the strategies, challenges, and best practices of scaling beyond the Asia Pacific MedTech market.
MedTech
Events October 7, 2022
Debate Sobre los IPT en Oncología
We are pleased to announce our next event, “Debate Sobre los IPT en Oncología,” focusing on price and reimbursement (P&R) of vital oncology and oncohematology therapies.
Market Access Product Development Regulatory
Events October 6, 2022
The MedTech Conference 2022
We are pleased to share that we will be joining the MedTech Conference 2022 as sponsors and speakers! This year’s edition will have more than 100 sessions focusing on today’s hot topics.
M&A MedTech Regulatory
News October 4, 2022
Alira Health enhances its market access services through a strategic partnership with Centivis
Alira Health, a global healthcare advisory and technology company, announced a strategic partnership with Centivis AG, a boutique market access consulting agency, specializing in digital(...)
Digital Health Market Access MedTech Pharma Regulatory
Multimedia September 29, 2022
Webinar Replay: Regulatory Strategy for Registering Rare Disease Products in the EU
In this webinar we will focus on how to benefit, today and in the future, from the orphan drug program and build a regulatory strategy for successful rare disease product registration(...)
Drug Development Rare Disease Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.